Mrs Jenna Katherine Walton, MS, CCC-SLP | |
862 Cassidy Pike, Ewing, KY 41039-8498 | |
(606) 748-1719 | |
Not Available |
Full Name | Mrs Jenna Katherine Walton |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 862 Cassidy Pike, Ewing, Kentucky |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1184902041 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | (Kentucky) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Jenna Katherine Walton, MS, CCC-SLP 779 Pecks Ridge Rd, Flemingsburg, KY 41041-8511 Ph: (606) 748-0593 | Mrs Jenna Katherine Walton, MS, CCC-SLP 862 Cassidy Pike, Ewing, KY 41039-8498 Ph: (606) 748-1719 |
News Archive
The Los Angeles Times: Obama administration officials at a meeting in Los Angeles Thursday touted their efforts to crack down on health care fraud, "saying quickly expanding criminal enterprises are costing taxpayers billions of dollars each year. ... Atty. Gen. Eric H. Holder Jr. and Health and Human Services Secretary Kathleen Sebelius said their agencies were jointly targeting fraud in the federal Medicare and Medicaid programs.
A major global study of what happens to consumer goods and other engineered products at the end of their useful life has found widespread use of unsafe management and disposal practices and calls for urgent action to address the risks posed to human life and health.
Athanasios Zavras began receiving messages from distraught patients in 2005 after case reports linked oral osteoporosis meds to bone death in the jaw.
Researchers in the Center for Translational Medicine at the University of Montana have been awarded $2.5 million in funding from the National Institutes of Health to identify and advance a COVID-19 vaccine candidate.
A team led by Michael Trauner at MedUni Vienna's Division of Gastroenterology and Hepatology demonstrated the beneficial effect of synthetically produced bile acid with the active agent nor-ursodeoxycholic acid (nor-urso) in the hitherto incurable liver disease primary sclerosing cholangitis (PSC) around two years ago.
› Verified 7 days ago
Deborah J Campbell, MASLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 862 Cassidy Pike, Ewing, KY 41039 Phone: 606-748-1719 |